Cargando…

Albumin administration in the acutely ill: what is new and where next?

Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawback...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Jean-Louis, Russell, James A, Jacob, Matthias, Martin, Greg, Guidet, Bertrand, Wernerman, Jan, Roca, Ricard Ferrer, McCluskey, Stuart A, Gattinoni, Luciano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223404/
https://www.ncbi.nlm.nih.gov/pubmed/25042164
http://dx.doi.org/10.1186/cc13991
_version_ 1782343191497801728
author Vincent, Jean-Louis
Russell, James A
Jacob, Matthias
Martin, Greg
Guidet, Bertrand
Wernerman, Jan
Roca, Ricard Ferrer
McCluskey, Stuart A
Gattinoni, Luciano
author_facet Vincent, Jean-Louis
Russell, James A
Jacob, Matthias
Martin, Greg
Guidet, Bertrand
Wernerman, Jan
Roca, Ricard Ferrer
McCluskey, Stuart A
Gattinoni, Luciano
author_sort Vincent, Jean-Louis
collection PubMed
description Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients.
format Online
Article
Text
id pubmed-4223404
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42234042015-07-16 Albumin administration in the acutely ill: what is new and where next? Vincent, Jean-Louis Russell, James A Jacob, Matthias Martin, Greg Guidet, Bertrand Wernerman, Jan Roca, Ricard Ferrer McCluskey, Stuart A Gattinoni, Luciano Crit Care Review Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients. BioMed Central 2014 2014-07-16 /pmc/articles/PMC4223404/ /pubmed/25042164 http://dx.doi.org/10.1186/cc13991 Text en Copyright © 2014 Vincent et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Vincent, Jean-Louis
Russell, James A
Jacob, Matthias
Martin, Greg
Guidet, Bertrand
Wernerman, Jan
Roca, Ricard Ferrer
McCluskey, Stuart A
Gattinoni, Luciano
Albumin administration in the acutely ill: what is new and where next?
title Albumin administration in the acutely ill: what is new and where next?
title_full Albumin administration in the acutely ill: what is new and where next?
title_fullStr Albumin administration in the acutely ill: what is new and where next?
title_full_unstemmed Albumin administration in the acutely ill: what is new and where next?
title_short Albumin administration in the acutely ill: what is new and where next?
title_sort albumin administration in the acutely ill: what is new and where next?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223404/
https://www.ncbi.nlm.nih.gov/pubmed/25042164
http://dx.doi.org/10.1186/cc13991
work_keys_str_mv AT vincentjeanlouis albuminadministrationintheacutelyillwhatisnewandwherenext
AT russelljamesa albuminadministrationintheacutelyillwhatisnewandwherenext
AT jacobmatthias albuminadministrationintheacutelyillwhatisnewandwherenext
AT martingreg albuminadministrationintheacutelyillwhatisnewandwherenext
AT guidetbertrand albuminadministrationintheacutelyillwhatisnewandwherenext
AT wernermanjan albuminadministrationintheacutelyillwhatisnewandwherenext
AT rocaricardferrer albuminadministrationintheacutelyillwhatisnewandwherenext
AT mccluskeystuarta albuminadministrationintheacutelyillwhatisnewandwherenext
AT gattinoniluciano albuminadministrationintheacutelyillwhatisnewandwherenext